蔺宇,王超

• 1:天津市南开医院心内科

摘要(Abstract)：

目的拟对急性ST段抬高心肌梗死伴呕吐患者,应用替罗非班弥补由于呕吐而导致的抗血小板药物摄入不足,进而探讨替罗非班对患者血小板聚集率的影响。方法 2009年12月至2011年12月南开医院心内科收治的,急性ST段抬高心肌梗死并接受急诊经皮冠状动脉介入治疗(PCI)的患者287例,其中服用双联抗血小板药物时发生呕吐者66例(23.0%)。将66例患者随机分为替罗非班组(33例)和常规治疗组(33例)。替罗非班组:呕吐后立即使用替罗非班[静脉推注10μg/kg,继以0.15μg/(kg·min)滴注,持续24~36 h];常规组:不使用替罗非班。所有患者在PCI术后12~24 h使用血栓弹力图(TEG)仪测定血小板聚集率。结果替罗非班组比常规组血小板功能花生四烯酸(AA)抑制率[(77.59±11.11)%比(52.48±12.06)%,P<0.001]、腺苷二磷酸(ADP)抑制率[(75.69±12.30)%比(49.54±14.13)%,P<0.001]均显著升高,而血栓形成的最大幅度(MA)值则显著下降[(22.79±4.19)mm比(36.28±6.08)mm,P<0.001]。结论急性ST段抬高心肌梗死伴呕吐患者应用替罗非班可显著增强血小板抑制率,在此类高危患者中加用血小板糖蛋白Ⅱb/Ⅲa抑制剂类药物,能显著扭转因呕吐所致的抗血小板药物剂量不足诱发的血小板聚集抑制率减低。

关键词(KeyWords)： 急性ST段抬高心肌梗死;呕吐;替罗非班;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 蔺宇,王超

参考文献(References)：

• [1]张东凤,宋现涛,吕树铮,等.急性ST段抬高心肌梗死患者急诊经皮冠状动脉介入治疗无复流现象相关因素分析.中国介入心脏病学杂志,2013,21:305-309.
• [2]Gorog DA,Sweeny JM,Fuster V.Antiplatelet drug'resistance'.Part2:laboratory resistance to antiplatelet drugs-fact or artifact?Nat Rev Cardiol,2009,6:365-373.
• [3]Dent HE,Dewhurst NG,Mills SY,et al.Continuous PC6 wristband acupressure for relief of nausea and vomiting associated with acute myocardial infarction:a partially randomised,placebo-controlled trial.Complement Ther Med,2003,11:72-77.
• [4]Fuller EE,Alemu R,Harper JF,et al.Relation of nausea and vomiting in acute myocardial infarction to location of the infarct.Am J Cardiol,2009,104:1638-1640.
• [5]Michelson AD.Platelet function testing in cardiovascular diseases.Circulation,2004,110:e489-e493.
• [6]Bochsen L,Wiinberg B,Kjelgaard-Hansen M,et al.Evaluation of the TEG platelet mapping assay in blood donors.Thromb J,2007,5:3.
• [7]Artang R,Frandsen NJ,Nielsen JD.Application of basic and composite thrombel astography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study.Thromb J,2009,7:14.
• [8]Lev EI,Ramchandani M,Garg R,et al.Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery.J Thromb Thrombolysis,2007,24:15-21.
• [9]Di Castelnuovo A,de Gaetano G,Benedetta Donati M,et al.Platelet glycoprotein IIb/IIIapolymorphism and coronary artery disease:implications for clinical practice.Am J Pharmacogenomics,2005,5:93-99.